Hemophilia A - Epidemiology Forecast - 2032

DelveInsight's 'Hemophilia A- Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered:

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Hemophilia A Disease Understanding

Hemophilia A Overview

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Athough hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.

Hemophilia A Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent Cases of Hemophilia A, Age-specific Prevalent Cases of Hemophilia A, Severity-specific Prevalent Cases of Hemophilia A, Prevalent Cases of Hemophilia A with or without Inhibitors and the treated pool of Hemophilia A in the 7MM market covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the Hemophilia A epidemiology in the 7MM

Country Wise- Hemophilia A Epidemiology

• The epidemiology segment also provides the Hemophilia A epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The total prevalent population of Hemophilia A in the 7MM comprised of 45,149 cases in 2021 and are projected to increase during the forecast period.
• The total prevalent population of primary brain cancer in the United States is 14,146 in 2021.
• The United States contributed to the largest prevalent population of Hemophilia A, accounting for ~ 31% of the 7MM in 2021.
• In the EU-5 countries, the diagnosed prevalence of Hemophilia A was found to be maximum in France followed by UK. While, the least number of cases were found in Spain, in 2021.
• In Japan, the total prevalent population of Hemophilia A is 5,542 in 2021 and is anticipated to rise during the forecast period.
• In 2021, the prevalent cases of mild in the United States were identified to be 3,360, moderate as 2,688 and severe as 7,391.
• In the US 2,217 cases accounts for inhibitor and 11,221 cases for non-inhibitor in 2021

Scope of the Report:

• The report covers the descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
• Comprehensive insight has been provided into the Hemophilia A epidemiology and treatment.
• The report provides insight about the historical and forecasted patient pool of Huntington's disease in seven major markets covering the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• A detailed review of Hemophilia A market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Hemophilia A market.
• The report also encompasses other major segments, i.e., age-specific, severity-specific cases of hemophilia A, prevalent pool based on inhibitor and non-inhibitor segment, and treated pool of Hemophilia A

Report Highlights:

• Eleven Years Forecast
• 7MM Coverage
• Total prevalent cases of hemophilia A
• Age-specific cases of hemophilia A

Hemophilia A Report Insights

• Patient Population
• Eleven Years Forecast
• 7MM Coverage
• Hemophilia A Epidemiology Segmentation

Key Questions

• What is the disease risk, burden and unmet needs of Hemophilia A?
• What is the historical Hemophilia A patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Hemophilia A at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hemophilia A?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Hemophilia A during the study period (2019-2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A.
• To understand the future market competition in the Hemophilia A market and Insightful review of the key market drivers and barriers.
• Quantify patient populations in the global Hemophilia A market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• The Hemophilia A Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.